Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Christen Maria Mowad MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · February 22, 2023

Efficacy of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Ali Alikhan MD

The Lancet

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Lancet 2023 Feb 03;[EPub Ahead of Print], AB Kimball, GBE Jemec, A Alavi, Z Reguiai, AB Gottlieb, FG Bechara, C Paul, EJ Giamarellos Bourboulis, AP Villani, A Schwinn, F Ruëff, L Pillay Ramaya, A Reich, I Lobo, R Sinclair, T Passeron, A Martorell, P Mendes-Bastos, G Kokolakis, PA Becherel, MB Wozniak, AL Martinez, X Wei, L Uhlmann, A Passera, D Keefe, R Martin, C Field, L Chen, M Vandemeulebroecke, S Ravichandran, E Muscianisi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Efficacy of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa

Additional Info

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Further Reading

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Recently Updated